In re Generic Pharmaceuticals Pricing Antitrust Litigation

Updated: February 08, 2017
Status: Ongoing Case

Labaton Sucharow continues to lead the charge in recent pay-for-delay cases against some of the largest pharmaceutical companies in the world. To date, nearly 80 class actions have been filed regarding 13 drugs, in which the Firm was first to file in several. The alleged misconduct—unlawfully raising prices of dozens of key generic drugs sold in the United States—has resulted in third-party payors, health and welfare funds, and consumers overpaying for prescription generic drugs.

At the same time, a federal criminal investigation, led by the Antitrust Division of the United States Department of Justice (DOJ), and a 40-state investigation, led by the Attorney General of Connecticut, are underway. In addition, there is a Congressional investigation into this same conduct being led by Senator Bernie Sanders and Representative Elijah Cummings.

In addition to actively monitoring the state and federal investigations, for the past two years, Labaton Sucharow has been conducting its own independent investigation into price-fixing in the generic pharmaceuticals industry. As a result of our investigation, we have been at the forefront in bringing cases on behalf of our clients; we were the first firm to bring claims alleging conspiracies involving albuterol sulfate, benazepril, divalproex, and glyburide, and the second to file cases involving digoxin, doxycycline, and pravastatin. To date, we have filed class actions alleging anticompetitive conspiracies involving 13 generic drugs.

In In re Generic Digoxin and Doxycycline Antitrust Litigation, on November 28, 2016, the court appointed Labaton Sucharow and its Antitrust and Competition Litigation co-chair Gregory Asciolla to the Plaintiffs’ Steering Committee.